Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis

Lancet

Volumn 357, Issue 9251, 2001, Pages 196-197

  Nishiguchi, Shuhei ^a   Shiomi, Susumu ^a   Nakatani, Shinji ^a   Takeda, Tadashi ^a   Fukuda, Katsuhiko ^a   Tamori, Akihiro ^a   Habu, Daiki ^a   Tanaka, Takashi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ANTIBODY RESPONSE; ARTICLE; CHRONIC ACTIVE HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

EID: 0035915622     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03595-9     Document Type: Article

References (5)

1. Randomised trial of effects of interfereon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
2. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States
3. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease
4. International Interferon-α Hepatocellular Carcinoma Study Group. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study
5. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan